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The Janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway is 
utilized by a range of cytokines (interferons, IL-2 and IL-6 amongst others) that control 
survival, proliferation and differentiation responses in diverse cell types. The realisation that 
unregulated activation of this pathway is a key driver of not only chronic inflammatory 
diseases such as rheumatoid arthritis, colitis and psoriasis, but also many cancers has 
identified its components as targets for therapeutic intervention by small molecule 
inhibitors and biologicals. In this article, we will discuss how an increased understanding of 
JAK-STAT pathway architecture, the basis for its dysfunction in pathological states, and its 
regulation by other intracellular signaling pathways are illuminating multiple strategies to 
manipulate this pathway in several disease arenas. 
2. Basic architecture of the JAK-STAT pathway 
2.1 Janus Kinases (JAKs) 
JAKs encompass a family of four of cytoplasmic tyrosine kinases (JAK1–JAK3, TYK2) that 
function as essential signaling components immediately downstream of receptors for many 
haematopoietic cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-
CSF), erythropoietin (Epo), interferons (IFNs), interleukins (e.g. IL-2, IL-6) as well as growth 
hormone and leptin. While JAK1, JAK2 and TYK2 are widely expressed, JAK3 expression is 
limited to haematopoietic cells where it is used by the receptors for a selected group of 
cytokines that are critical in T cell, B cell and natural killer cell development (Ghoreschi et 
al., 2009). Importantly, functional deficiencies in JAK3 have been shown to account for 
autosomal recessive “severe combined immunodeficiency” (SCID) syndrome (O’Shea et al., 
2004). However, despite these differences, JAKs are thought to function downstream of 
individual cytokine receptors in a similar manner. 
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Structurally JAKs comprise seven conserved domains (JAK homology (JH) domains 1-7) 
numbered from the carboxyl to the amino terminus (Fig. 1). The hallmark of the JAK family 
is the presence of JH1, which comprises a functional tyrosine kinase domain, and JH2, which 
was originally thought to be a catalytically inactive pseudokinase domain. However, it has 
recently been demonstrated that the JAK2 JH2 has dual-specificity protein kinase activity 
that phosphorylates Ser523 and Tyr570, which are critical negative regulatory sites, although 
the specific kinase activity of JH2 is approximately ten-fold less than that of JH1 (Ungureanu 
et al., 2011). It had long been established that JH2 has a negative regulatory function, as 
deletion of this domain has been shown to increase JAK2 and JAK3 phosphorylation and 
downstream activation of STATs. This is achieved via an intramolecular interaction between 
JH1 and JH2, which effectively suppresses basal kinase activity. Upon ligand binding, 
conformational changes relieve this interaction allowing activation of JH1 by 
phosphorylation of two activation loop Tyr residues (Tyr 1021/1022 in JAK1, Tyr 1007/1008 
in JAK2, Tyr 980/981 in JAK3, Tyr 1054/1055 in TYK2) (Saharinen et al., 2000; Saharinen & 
Silvennoinen, 2002). Abrogation of JH2’s dual specificity kinase activity was found to be 
sufficient to increase basal JAK2 activity and downstream signaling to STAT1, suggesting 
that this is a key element of the JH2 domain’s suppressive effect on JH1. As described later 
in this chapter, this provides an essential “braking” function as mutations that disrupt the 
JH2 domain’s suppression of JH1 activity are found in several haematological disorders. 
 
Fig. 1. Domain structure of human JAK2. The crystal structure of the JAK2 JH1 domain 
bound to JAK inhibitor tofacitinib is reproduced from Williams et al. (2009) with permission. 
JH3-5 comprise an SH2 domain typically indicative of PTyr-dependent interactions with 
other signaling components but surprisingly partners for this domain have yet to be 
identified for any of the JAK family (Ingley & Klinken, 2006). Lastly, JH6-JH7 constitute a 
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Band 4.1, ezrin, radaxin, moesin (FERM) domain implicated in interactions with cytokine 
receptors required for cell surface expression (Huang et al., 2001) and also the JH1 domain 
to regulate its kinase activity (Zhou et al., 2001). 
JAKs have typically been thought to be constitutively associated with dimeric cytokine 
receptor complexes at the plasma membrane, although a role for nuclear-localised JAKs in 
controlling the phosphorylation of histone H3 has emerged that may be particularly 
important in haematological malgnancies and embryonic stem cell renewal (Dawson et al., 
2009; Griffiths et al., 2011). However, following cytokine binding, a conformational change 
within the dimeric receptor complex allows activation of receptor-bound JAKs due to 
transphosphorylation of JH1 activation loop Tyr residues. The structural basis of the JAK-
receptor interaction and the mechanism by which the receptor re-orientates to receive the 
phosphorylation are currently unclear and the subject of intense research (Lupardus et al., 
2011). Nevertheless, after receptors have been phosphorylated at specific Tyr residues, SH2 
domain-containing proteins are recruited to activate downstream signaling. The major 
intracellular mediators commonly activated by multiple cytokine receptors are the signal 
transducer and activator of transcription (STAT) proteins. 
2.2 Signal Transducers and Activators Of Transcription (STATs) 
The STAT family of transcription factors were first described as interferon (IFN)-inducible 
transcription factors (Fu, 1992; reviewed by Darnell et al., 1994;). The STAT family comprises 
seven mammalian members (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6). 
However alternative splicing of STAT1, 3, 4, 5a and 5b primary transcripts yields isoforms 
with truncated C-terminal domains; for example the STAT3ǃ isoform lacks the 55 C-
terminal amino acids of STAT3ǂ but acquires a unique 7 amino acid sequence (Dewilde et 
al., 2008). While the ǃ isoforms have been reported to act as dominant negative regulators of 
transcription, it is now apparent that these isoforms can differ in their transcriptional 
activities, for example isoform-specific deletions of STAT3ǃ and STAT3ǂ have shown that 
STAT3ǃ activates a distinct subset of STAT3 genes in response to IL-6 and may not act as a 
dominant negative in vivo (Maritano et al., 2004; Dewilde et al., 2008). Exactly how the 
discrete functional differences observed between STAT3ǂ and STAT3ǃ relate to their 
distinct subcellular trafficking kinetics remains to be determined (Huang et al., 2007). 
STATs are activated by a wide range of cytokines and other growth factors. Depending on 
the cell type involved, a range of sometimes overlapping ligands can activate STAT1, 
STAT3, STAT5a and STAT5b, whereas only a few cytokines are capable of activating STAT2, 
STAT4 and STAT6 (Lim & Cao, 2006). For example, in addition to multiple IL-6 family 
members, STAT3 can also be activated by G-protein coupled receptors for angiotensin II and 
thrombin, as well as the VEGFR2 receptor tyrosine kinase (Madamanchi et al., 2001; Pelletier 
et al., 2003; Bartoli et al., 2000). Functionally, STAT3 has been implicated in cell proliferation, 
survival and anti-apoptotic responses in multiple cell types (Yu et al., 2009). Conversely, 
STAT6 is predominantly activated by IL-4 and is involved in the differentiation of CD4+ T 
cells into T helper 2 (Th2) cells (Hebenstreit et al., 2006). 
Structurally, STATs comprise several distinct functional domains; these include an N-
terminal domain, a coiled-coil domain, a DNA binding domain, a linker domain, an SH2 
domain and a C-terminal transactivation domain. The N-terminal domain is involved in 
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STAT dimerisation and tetramerisation, and for some STATs the recruitment of regulatory 
proteins such as STAT E3 ubiquitin ligase SLIM (Tanaka et al., 2005). The coiled-coil domain 
is also implicated in protein-protein interactions; for example, the transcription factor c-Jun 
has been demonstrated to interact with this domain in STAT3, facilitating co-operation 
required for maximal IL-6-dependent acute-phase response gene activation driven by the 2-
macroglobulin enhancer (Zhang et al., 1999b). This domain may also be involved in 
ensuring high affinity binding to cytokine receptors, as mutations within it impair 
recruitment of STAT3 to Tyr-phosphorylated gp130 (Zhang et al., 2000). The DNA-binding 
domain is highly conserved amongst the STAT family and as well as binding DNA, it also 
controls STAT translocation from the cytoplasm to the nucleus. It has been proposed to 
achieve this by maintaining the necessary conformation for binding of importins on the 
nuclear membrane (Ma & Cao, 2006). Once in the nucleus, STAT dimers can bind DNA 
motifs known as GAS ( activated sequence) elements (TTN5-6AA, N=any nucleotide) except 
in the case of the IFN response, where complexes formed between STAT1, STAT2 and 
IRF9 (interferon regulatory factor 9) bind to the IFN-response element (ISRE) 
AGTTN3TTTC (O’Shea et al., 2002). The linker domain has been implicated in 
transcriptional activation, since point mutations within this region of STAT1 have been 
found to abolish transcriptional responses to IFN (Yang et al., 1999). Additionally, this 
domain also participates in distinct protein-protein interactions, as demonstrated by the 
interaction of STAT3 with “genes associated with retinoid–IFN-induced mortality-19” 
(GRIM-19), which blocks STAT3-mediated transcriptional activity (Kalakonda  et al., 2007). 
The most conserved domain within the STAT family is the SH2 domain. This domain is 
essential for binding to activated receptors and is also responsible for cytokine-triggered 
dimerisation via specific phospho-Tyr residues (Shuai et al., 1994; Hemmann et al., 1996). 
Different receptor motifs determine which STATs are recruited; for example, STAT3 will 
bind to pYXXQ (Stahl et al., 1995) while STAT1 will only bind to pYXPQ (Gerhartz et al., 
1996). This difference has been shown to be due to the SH2 domain through the creation of a 
chimaeric STAT3 molecule in which the SH2 domain of STAT3 was substituted with a 
STAT1 SH2 domain, resulting in a molecule that showed the receptor motif binding 
preference of STAT1 (Hemmann et al., 1996). On recruitment to an activated cytokine 
receptor, STATs are then phosphorylated by JAKs on a single conserved tyrosine residue at 
the carboxyl end of the SH2 domain (e.g. Tyr701 in STAT1 (Shuai et al., 1994) and Tyr705 in 
STAT3 (Kaptein et al., 1996)). This enables them to form dimers through an interaction of the 
P-Tyr on one STAT with the SH2 domain of another. 
Lastly, the C-terminal transactivation domain mediates protein-protein interactions 
necessary for optimal transcriptional activation; these include interactions with the  
transcriptional co-activators “cAMP response element binding protein” (CREB)-binding 
protein (CBP) and p300 (Paulson et al., 1999). In the cases of STAT1 and STAT3, optimal 
interaction with p300/CBP requires phosphorylation of Ser727 by any of several Ser/Thr 
kinases, including extracellular signal-regulated kinases 1 and 2 (ERK1,2) (Schuringa et al., 
2001; Heinrich et al., 2003). 
To demonstrate how these proteins function in context, we will describe signaling pathway 
activation in response to the activation of two key cytokine receptor systems implicated in 
several haematological and non-haematological conditions: the IL-6 and IFN signaling 
complexes. 
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2.3 Activation of the JAK-STAT and ERK1,2 pathways by IL-6 
The IL-6 receptor is composed of two different subunits, an 80 kDa IL-6-binding protein (IL-
6R) and a 130 kDa signal-transducing subunit (gp130), which is shared by all IL-6-family 
cytokines, which include IL-11, IL-27, oncostatin M, leukaemia inhibitory factor (LIF), 
cardiotrophin-1 (CT-1) and ciliary neurotrophic factor (CNTF) amongst others (Heinrich et 
al., 2003). The gp130 subunit is ubiquitously expressed while IL-6R expression is restricted 
to hepatocytes, monocytes, neutrophils and some B and T cell subsets. However, IL-6 can 
also bind to a soluble form of the receptor (sIL- 6R) which is either shed from cell 
membranes by limited proteolytic cleavage of membrane-bound IL-6Rǂ by the 
metalloproteinases ADAM10 and ADAM17  or created by alternative splicing of IL-6R 
primary transcripts (Kallen, 2002). The resulting sIL-6R/IL-6 so-called “trans-signaling” 
complex can associate with gp130 on cells that do not express the membrane-bound IL-6R 
thereby widening the spectrum of IL-6-responsive cells. For example, vascular endothelial 
cells which express only gp130 are rendered responsive to IL-6 due to the shedding of sIL-
6Rfrom activated neutrophils (Marin et al., 2001). 
Binding of the trans-signaling complex to gp130 or the interaction of IL-6 with IL-6R 
triggers dimerisation of the gp130 subunits and the formation of an active receptor signaling 
complex (Murakami et al., 1993; Fig. 3). JAK1, JAK2 and TYK2 have each been shown to be 
activated upon receptor stimulation (Stahl et al., 1994; Narazaki et al., 1994) and can 
phosphorylate gp130 on Tyr’s 683, 759, 767, 814, 905 and 915 (Stahl et al., 1994; Stahl et al., 
1995; Gerhartz et al., 1996). (Fig. 2)  Studies using cell lines lacking either JAK1, JAK2 or 
TYK2 have revealed that whereas JAK2 and TYK2 may be functionally interchangeable, 
effective  downstream signaling absolutely depends on the presence of JAK1 (Guschin et al., 
1995). Thus, phosphorylation of gp130 was demonstrated to be significantly reduced in the 
absence of JAK1 but was unimpaired in the absence of either JAK2 or TYK2. The membrane-
proximal regions of gp130 are predominantly responsible for binding JAK1. These regions 
contain conserved box1 and box2 motifs which are both required for efficient JAK binding. 
Either deletions or mutations to box1 result in the impaired binding of JAKs to gp130 (Haan 
et al., 2000) while deletion of box2 only leads to JAK association when the kinase is over-
expressed (Tanner et al., 1995), suggesting that box2 increases the affinity of JAK binding. In 
addition, an interbox1-2 region on gp130 is also involved in JAK binding and again, in 
studies where this region has been mutated, defective JAK signaling has been observed 
(Haan et al., 2000). 
All IL-6 type cytokines are capable of activating STAT1 and STAT3 via gp130. However, 
STAT3 activation has been observed to a greater extent than STAT1 activation (Heinrich et 
al., 2003). STAT recruitment to activated IL-6 type receptors is mediated by the STAT SH2 
domain and requires the phosphorylation of specific Tyr residues. In particular, STAT3 
binds four phospho pYXXQ motifs of gp130 (Y767RHQ, Y814FKQ, Y905LPQ and Y915MPQ) 
(Stahl et al., 1995), whereas STAT1 is more restricted and binds two pYXPQ motifs in gp130 
(Y905LPQ and Y915MPQ) (Gerhartz et al., 1996) (Fig. 2). Once recruited, STATs are 
phosphorylated by JAKs on a single Tyr residue (Tyr701 in STAT1 and Tyr705 in STAT3 
(Kaptein et al., 1996; Shuai et al., 1993) (Fig. 2). In addition, as discussed earlier, both STAT1 
and STAT3 can be phosphorylated by ERK1,2 on Ser727 to enhance p300/CBP recruitment 
for maximal transcriptional activity (Schuringa et al., 2001; Heinrich et al., 2003). Following 
phosphorylation, activated STATs form homo- and/or hetero-dimer complexes, consisting 
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of STAT1-STAT1, STAT1-STAT3 or STAT3-STAT3 dimers, which translocate to the nucleus 
to bind response elements of IL-6 inducible genes. STATs bind to essentially two types of 
response elements; interferon stimulated response elements (ISREs) and gamma-activated 
sites (GAS). The ISRE appears to be restricted to IFN signaling (Fu et al., 1990), whereas the 
GAS, including sis-inducible element (SIE), acute phase response element (APRE) and other 
GAS-like sequences are present in promoters of genes such as c-fos and the acute phase 
proteins that are well-defined STAT targets (Wegenka et al., 1993). Other target genes 
downstream of STAT3 include cell cycle regulators such as cyclin D1, and anti-apoptotic 
genes such as survivin and Bcl-XL (Alvarez & Frank., 2004). 
 
Fig. 2. JAK-mediated activation of ERK1,2 and STATs via gp130 
Finally, it should be emphasized that SHP2 (SH2-domain-containing cytoplasmic protein 
tyrosine phosphatase), a ubiquitously expressed and highly conserved PTP, is also recruited to 
the activated IL-6 receptor. SHP2 comprises two N-terminal SH2 domains and a C-terminal 
PTP domain. It is recruited to pTyr759 on gp130 following receptor activation and is 
subsequently phosphorylated by JAKs. The phosphorylation of SHP2 provides SH2 domain 
docking sites for the adapter protein Grb2 (growth factor receptor binding protein 2), which is 
constitutively associated with the Ras guanine nucleotide exchange factor Son of sevenless 
(Sos) (Fig. 2). It has been proposed that the C-terminal domain residues Tyr542 and Tyr580 
within SHP2 interact with the Grb2-Sos complex (Heinrich et al., 2003). Sos recruitment to the 
receptor complex allows for the activation of Ras at the plasma membrane, which in turn leads 
to the activation of the Ras-Raf-MEK-ERK1,2 cascade. ERK1,2 activation results in the 
preferential phosphorylation of substrates with the consensus sequence PXS/TP and more 
than 150 substrates have been identified to date (Yoon & Seger, 2006). 
2.4 Activation of the JAK-STAT pathway by interferons (IFNs) 
The IFNs comprise three families of secreted proteins that work in both an autocrine and 
paracrine manner to trigger intracellular signaling networks designed to combat viral 
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infection. Type I IFNs in humans are derived from seventeen genes clustered within 
chromosome 9. In humans, type I IFNs comprise thirteen IFN’s and a single version of 
each of IFN, ,  and  (Borden et al., 2007). Interestingly, expression of IFN-ǋ and IFN-ε 
seems tissue specific, but all cells have the potential to produce other IFNs although the 
spectrum of  IFNs actually induced appears to vary in a stimulus-specific manner (LaFleur 
et al., 2001; Hardy et al., 2004). IFNǄ is designated as a distinct type II IFN because of its 
distant sequence homology with the type I IFNs, as well as its production by natural killer 
(NK) or activated T cells. The type III IFN family comprises three IFN-ǌ subtypes which are 
co-produced with IFN-ǃ, and which activate the same main signaling pathways as type I 
IFNs but via different receptor complexes (Borden et al., 2007). 
2.4.1 IFN signaling 
The functional IFN receptor (IFNGR) comprises two 90 kDa IFNGR1 and two 62 kDa 
IFNGR2 chains. IFNGR1 is involved in ligand binding and signal transduction while 
IFNGR2 has a limited role in binding but is essential for downstream signaling (Stark et al., 
1998). Originally, these subunits were not thought to interact in unstimulated cells but 
advances in imaging techniques in living cells have shown that the receptor is pre-
assembled and ligand binding results in a conformational change to allow signaling to occur 
(Krause et al., 2002). IFNGR1 and IFNGR2 have binding motifs for JAK1 and JAK2 
respectively. JAK1 binds to the membrane proximal sequence, L266PKS on IFNGR1 (Kaplan 
et al., 1996) while JAK2 binds a Pro-rich noncontiguous motif of P263PSIP followed by 
I270EEYL on IFNGR2 (Bach et al., 1996). 
Upon receptor activation, JAK2 is autophosphorylated, enabling it to trans-phosphorylate 
JAK1 (Briscoe et al., 1996). The activated JAKs then phosphorylate each IFNGR1 chain on 
Tyr440 within the sequence Y440DKPH, which creates a pair of docking sites for STAT1 SH2 
domains. STAT1 is then phosphorylated on Tyr701, dissociates from the receptor, forms 
homodimers and translocates to the nucleus. Activation of the phosphatidylinositol 3-kinase 
(PI3K) pathway also appears to play a role in IFN-induced STAT1-mediated transcriptional 
regulation, as inhibition of either PI3K or one of its downstream effectors, protein kinase C  
(PKC), blocks STAT1 phosphorylation on Ser727, thus reducing its transcriptional activity. 
Therefore, since IFN has been shown to activate PKC in a PI3K dependent manner, it has 
been suggested that PKC is an IFN-regulated Ser 727 kinase for STAT1 (Nguyen et al., 
2001; Deb et al., 2003), although a role for PKC-activated p38 MAP kinase has recently 
emerged (Borden et al., 2007). 
2.4.2 IFN signaling 
Type I IFNs belong to the cytokine group that display similar secondary structures of a five 
ǂ-helix bundle stabilized by two disulphide bonds (Borden et al., 2007). Binding of type I 
IFNs to their cognate receptor complex, which comprises one chain each of IFNAR1 and 
IFNAR2c, activates TYK2 and JAK1 constitutively associated on the respective chains. 
Interestingly, the intracellular domain of IFNAR2c plays the key role in the recruitment and 
docking of STATs while deletion of much of the cytoplasmic domain of IFNAR1 is without 
effect on signaling. The presence of a single Tyr residue within the IFNAR2c  cytoplasmic 
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domain (either Tyr337 or Tyr512) is required for a full IFN response from this receptor 
(Borden et al., 2007; van Boxel-Dezaire & Stark, 2007). 
Activated TYK2 then phosphorylates receptor-bound STAT2, an essential component of  
type I IFN signaling, on Tyr690 allowing it to interact with STAT1, which is then 
phosphorylated on Tyr701. STAT1 and STAT2 form a heterodimeric complex which 
dissociates from the receptor and translocates to the nucleus. It is now apparent that type I 
IFNs can activate all  STAT members, but the transcription factor complex unique to type I 
IFNs is ISGF3 (IFN-stimulated gene factor 3), a trimeric complex of STAT1, STAT2 and a 
48kDa DNA-binding protein IRF9 (IFN regulatory factor 9). Upon nuclear import, the 
STAT1 and IRF9 components of the complex specifically bind ISREs within target gene 
promoters. STAT2 does not contribute to the DNA binding activity of the ISGF3 complex, 
instead contributing a powerful C-terminal transactivation domain responsible for 
recruitment of p300/CBP co-activators (Borden et al., 2007). 
3. Negative regulation of cytokine signaling 
Cytokine signaling is typically transient, suggesting the involvement of negative regulatory 
steps aimed at terminating or resolving responses. Indeed, controlling these responses is 
crucial for avoiding detrimental inflammatory outcomes, including the development of 
diseases such as rheumatoid arthrisis (RA), Crohn’s disease and Castleman’s disease. There 
are many mechanisms with which to negatively control cytokine signaling but for the 
purposes of this chapter we will focus on soluble ligand traps, suppressors of cytokine 
signaling (SOCS) proteins and PTPs. 
3.1 Soluble ligand traps 
As previously mentioned, the IL-6 receptor is composed of two different subunits, an 80 kDa 
IL-6R and a 130 kDa signal-transducing gp130 subunit. A soluble form of the signal 
transducer protein gp130 (sgp130) was also detected in the circulation at relatively high 
concentrations (100–400 ng/ml in human plasma) (Narazaki et al., 1993; Chalaris et al., 
2011). Sgp130 is produced by alternative splicing and has been shown to bind the sIL-6R/IL-
6 complex in the circulation, thus acting as a selective inhibitor of IL-6 mediated trans-
signaling, as classic signaling via membrane-localised IL-6R is not affected (Muller-Newen et 
al., 1998). Moreover, sgp130 appears to be specific for the IL-6/sIL-6R complex since 
signaling from gp130 in response to other IL-6-type cytokines such as LIF and OSM were 
only inhibited at 100–1000-fold higher concentrations (Chalaris et al., 2011). 
As discussed later, the ability of either endogenous or genetically engineered soluble 
cytokine ligand traps to block binding to and activation of signaling from endogenous 
cytokine receptors has emerged as a very useful strategy to turn off excessive cytokine 
signaling associated with inflammatory and autoimmune diseases (Jones et al., 2011). In the 
case of IL-6, they have also increased our understanding of the contributions of classical 
versus trans-signaling in specific biological processes (Scheller et al., 2011). 
3.2 Suppressor of Cytokine Signaling (SOCS) proteins 
There are eight members of the suppressor of cytokine signaling (SOCS) family of proteins; 
CIS (cytokine-inducible SH2 domain-containing protein) and SOCS1 through to SOCS7 (Fig. 
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3). SOCS1 was the first member to be discovered in 1997 by three independent groups (Endo 
et al., 1997; Naka et al., 1997; Starr et al., 1997). Using the predicted amino acid sequence of 
SOCS1 as a probe, database searches identified 20 proteins with shared sequence homology 
within the C-terminal SOCS box region. Based on the presence of a central SH2 domain, the 
SOCS proteins were subdivided into a group of their own. The remaining proteins were 
divided into the following groups; WD-40-repeat proteins with a SOCS box (WSB proteins), 
ankyrin repeat proteins with a SOCS box (ASB proteins), sprouty (SPRY) domain-containing 
SOCS box proteins (SSB proteins) and GTPase domain-containing proteins (RAR and RAR-
like proteins) (Krebs & Hilton, 2001). In addition to a central SH2 domain, all members of 
the SOCS family contain an amino-terminal region of variable length (50-380 amino acids) 
and a conserved 40 amino acid carboxyl terminal “SOCS box” (Alexander, 2002; Yoshimura 
et al., 2007). Analysis of the primary amino acid sequences of all SOCS members has 
revealed paired associations according to sequence similarity. Thus, CIS/SOCS2, 
SOCS1/SOCS3, SOCS4/SOCS5 and SOSC6/SOCS7 form related pairs. CIS and SOCS1-3 are 
the best characterised members of the family, while the remainder are poorly understood in 
comparison. Since both SOCS1 and SOCS3 are well studied, homology-paired and have 
been shown to potently inhibit cytokine signaling, focus will be placed on these SOCS 
members in particular.  
 
Fig. 3. Elongin-Cullin-SOCS-box (ECS) family of E3 ubiquitin ligases. Structure taken from 
Piessevaux et al. (2008) with permission. 
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3.2.1 SOCS proteins as inhibitors of cytokine signaling 
SOCS proteins function as classical negative feedback inhibitors of cytokine signaling, since 
most SOCS proteins are themselves induced by cytokines. Cytokines shown to induce SOCS 
include the gp130 signaling cytokines, IL-2, IL-3, IL-4, IL-10, IFNs, G-CSF and leptin. 
(Alexander, 2002; Yoshimura et al., 2007). Other inducers include Toll-like receptor (TLR) 
agonists (e.g. LPS, CpG-DNA), growth hormone (GH), prolactin and cyclic AMP (cAMP) 
(Dalpke et al., 2001; Gasperini et al., 2002; Lang et al., 2003; Sands et al., 2006). The SOCS 
proteins can inhibit signaling by multiple mechanisms according to the SOCS member and 
signaling pathway involved. SOCS proteins can bind specific PTyr residues via their SH2 
domain. Thus, SOCS3 binds to PTyr759 (PTyr757 in mouse) on gp130 (Nicholson et al., 2000) 
and physically occupies the same sites as other SH2 domain-containing signaling 
components such as SHP2, thereby competing with and blocking activation of other 
signaling pathways (De Souza et al., 2002; Heinrich et al., 2003) (Fig. 2). In vitro studies have 
shown that the phospho-peptide binding specificity of SOCS3 is very similar to that of 
SHP2, with optimal SOCS3 and SHP2 phospho-peptide ligands containing overlapping 
consensus sequences (De Souza et al., 2002). The same group also demonstrated that SOCS3 
binds to the gp130 receptor with a much higher affinity than the leptin receptor ObRb. 
However, the finding that SOCS3 can bind two sites on the leptin receptor versus one site on 
gp130 may compensate for the low affinity each ObRb site exhibits (De Souza et al., 2002). 
The kinase inhibitory region (KIR) of SOCS1 and SOCS3, located upstream of the SH2 domain, 
is capable of interacting with the substrate binding site of the JH1 domain of JAKs, acting as a 
pseudosubstrate and thus inhibiting catalytic activity and downstream signaling from the 
associated receptor (Sasaki et al., 1999; Yasukawa et al., 1999). Specifically, Tyr31 of SOCS3 and 
Tyr65 of SOCS1 have been identified as the critical residues responsible for the 
pseudosubstrate inhibition of JAK2 (Bergamin et al., 2006). Interestingly, structural data 
relating to this interaction has revealed that it is implausible for Tyr31 or Tyr65 to reach the 
active kinase domain of JAK2 if bound via the SH2 domain i.e. in cis (Bergamin et al., 2006). 
This does not rule out the possibility that the SOCS proteins could bind to one JAK molecule 
via their SH2 domain and inhibit another JAK via pseudosubstrate inhibition i.e. in trans, or the 
possibility that binding of the SOCS SH2 domain to the specific PTyr residues positions the 
KIR for binding to the kinase domain of associated JAK2. The latter possibility appears to be 
the more likely scenario, since the crystal structure of the SOCS3/gp130 complex and various 
structural data favour the physiological target of SOCS3 SH2 domain to be pTyr757/759 of 
mouse/human gp130 and not the activation loop of JAK2 (Bergamin et al., 2006). 
The SOCS box present within all SOCS members can recruit elongins B and C, which 
together with cullin 5 and RING-box 2 (Rbx2) form an E3 ubiquitin-ligase complex (Fig. 3). 
This complex associates with enzymes E1, a ubiquitin-activating enzyme and E2, a 
ubiquitin-conjugating enzyme, to mediate Lys48 polyubiquitylation and subsequent 
proteasomal degradation of signaling components bound to the SOCS proteins via their SH2 
domains (Kamura et al., 2004; Ungureanu et al., 2002; Zhang et al., 1999a) (Fig. 3). A possible 
ubiquitination site, Lys-6 is also present at the N-terminus of SOCS3, and an N-terminally 
truncated isoform of SOCS3 lacking this site is significantly more stable than wild-type 
SOCS3, suggesting that polyubiquitylation of Lys6 plays an important role in regulating 
turnover. Moreover, this demonstrates one level by which SOCS3 expression can be 
regulated post-translationally (Sasaki et al., 2003). 
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SOCS proteins can theorectically target the whole receptor-cytokine complex including the 
JAKs, plus the SOCS proteins themselves, for proteasomal degradation. Therefore, it raises 
the question of how SOCS proteins selectively block JAK signaling at specific  receptors. 
This could possibly be explained by the realization that SOCS SH2 domains preferentially 
bind specific PTyr motifs on activated receptors rather than JAKs, thereby causing 
degradation of associated JAKs as well as the receptor-cytokine complex, and also achieving 
specificty at the receptor level. Indeed, it has been shown that mutation of the SOCS3 
binding site Tyr757 to non-phosphorylatable Phe on murine gp130 is sufficient to cause 
enhanced IL-6-inducible gene expression (Anhuf et al., 2000). Furthermore, bone marrow-
derived macrophages (BMDMs) isolated from mice with a Tyr757Phe mutation in gp130 
switch the IL-6 mediated response to an “IL-10-like‟ anti-inflammatory response, in terms of 
inhibiting LPS-induced induction of pro-inflammatory cytokines (El Kasmi et al., 2006). 
Previous studies have linked the absence of SOCS3 with the establishment of the anti-
inflammatory response following IL-6 treatment (Yasukawa et al., 2003), so the data 
suggests that mutation of only the specific PTyr that binds SOCS3 is sufficient to cause 
cytokine receptors to become refractory to SOCS inhibition, despite the presence of JAKs. 
This is in contrast to SOCS1, for which it has been shown that the phenotype of SOCS1-
deficient mice can only be partially rescued in mice with SOCS1 lacking the SOCS box, but 
retaining the SH2 domain. This shows that both the SOCS box and SH2 domain are required 
for the inhibitory effects on IFN-signaling (Zhang et al., 2001). Mice in which endogenous 
SOCS3 has been replaced with a truncated SOCS3 mutant lacking the SOCS box have been 
shown to be viable but exhibit hyper-responsivenenss to G-CSF, suggesting that linkage of 
SOCS3 to the ubiquitin machinery is important in restraining G-CSF signaling in vivo (Boyle 
et al., 2007), possibly through controlling the ubiquitination-mediated routing of the G-CSF 
receptor to lysosomes (Irandoust et al., 2007). 
In contrast to findings of SOCS interaction with elongins B and C leading to proteasomal 
degradation, some studies have found that interaction with the elongin BC complex can 
stabilise both SOCS3 (Haan et al., 2003) and SOCS1 (Kamura et al., 1998). Haan et al. (2003) 
showed that Tyr phosphorylation of SOCS3 disrupted interaction with elongins, which 
accelerated SOCS3 degradation. This may suggest that Tyr phosphorylation of SOCS3 is a 
prerequisite to its subsequent proteasomal degradation. Indeed, Haan et al. (2003) proposed 
that the elongin BC interaction with SOCS3 may function to associate SOCS3 with a latent 
ubiquitination complex that only becomes active when SOCS3 is phosphorylated. SOCS3 
phosphorylation on Tyr204 and/or Tyr221 causes the dissociation of elongin C and the 
bringing together of the ubiquitination machinery into close proximity with SOCS3, 
subsequently triggering its degradation (Haan et al., 2003). 
3.2.2 SOCS proteins as regulators of other Tyr phosphorylation-dependent pathways  
In addition to the involvement of SOCS proteins in cytokine signaling, SOCS1 and SOCS3 
have been shown to bind receptors for EGF and FGF receptors and affect downstream 
signaling events both positively and negatively (Ben-Zvi et al., 2006; Xia et al., 2002). With 
regards to EGF signaling, SOCS1 and 3 have been shown to facilitate EGFR proteasomal 
degradation in HEK293 cells (Xia et al., 2002), while SOCS1 has been shown to inhibit 
STAT1 phosphoryation and elevate ERK1,2 phosphorylation in response to FGF treatment 
of rat chondrosarcoma (RCS) cells (Ben-Zvi et al., 2006). Furthermore, SOCS1 and SOCS3 
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have both been shown to associate with insulin receptor substrates 1 (IRS1) and IRS2 
following insulin stimulation, and interact with the elongin BC ubiquitin-ligase complex to 
promote their polyubiquitylnation and subsequent degradation (Kawazoe et al., 2001; Rui et 
al., 2002). 
As mentioned earlier, SOCS3 offers another level of regulation by being able to become 
phosphorylated on Tyr204 and Tyr221 within the SOCS box in response to IL-2, Epo and 
other stimuli (Cacalano et al., 2001; Haan et al., 2003). Using a murine B cell line, it was 
found that WT SOCS3 could inhibit IL-2-mediated STAT5 phosphorylation, but maintain IL-
2-mediated ERK1,2 phosphorylation, whereas a Tyr204/221Phe double mutant SOCS3 still 
inhibited STAT5 phosphorylation, but in contrast to the WT, induced the abolition of 
ERK1,2 phosphorylation, suggesting a phosphorylation-dependent maintenance of ERK 
signaling. (Cacalano et al., 2001). The inhibitory effect of the mutant was also observed 
following Epo and PDGF treatment. Thus, phosphorylation of Tyr204 and Tyr221 of SOCS3 
following growth factor stimulation has been proposed to trigger PTyr221 interaction with 
the SH2 domain of RasGAP, thereby sustaining GTP accumulation on Ras and subsequent 
activation of ERK1,2. It is well established that the duration of ERK1,2 signaling is important 
for determining biological outcome; for example sustained activation of ERK has been 
shown to be required for the control of G1 progression by regulating cyclin D1 activation in 
some systems (Weber et al., 1997). SOCS3 therefore appears to have both pathway-specific 
and receptor-specific effects, and can positively regulate activation of specific signaling 
pathways, adding further complexities to its actions. 
An additional level of complexity demonstrated by SOCS proteins is their ability to interact 
with other SOCS family members (Piessevaux et al., 2006; Tannahill et al., 2005). For 
example, although SOCS2 plays a major role in the negative regulation of GH signaling 
(Greenhalgh et al., 2002), it has also been shown to enhance GH signaling. This is believed to 
be caused by the binding of SOCS2 to other SOCS members and modulating their activity 
via the elongin BC complex, with subsequent proteasomal degradation (Piessevaux et al., 
2006; Tannahill et al., 2005). This SOCS2-mediated inhibitory effect on other SOCS members 
has been observed on SOCS1- and SOCS3-dependent inhibition of GH signaling, thus 
potentiating it (Piessevaux et al., 2006). SOCS2 has also been shown to enhance IL-2 and IL-3 
signaling (Tannahill et al., 2005) by accelerating proteasome-dependent degradation of 
SOCS3. Similar effects again have been shown on signaling via the IFN type 1 and leptin 
receptors (Piessevaux et al., 2006). These observations imply that SOCS2 is counteracting the 
effects of other SOCS proteins, rather like a secondary negative feedback mechanism, to 
limit the effects of excessive levels of SOCS proteins. This assumption is supported by the 
findings that SOCS2 induction is usually initiated after a significant delay following 
cytokine stimulation and is prolonged, whereas SOCS1 and SOCS3 expression is typically 
rapid and transient (Adams et al., 1998). Although poorly understood, SOCS6 and SOCS7 
have also been shown to bind other SOCS members and similar effects to SOCS2 have been 
observed for SOCS6 (Piessevaux et al., 2006). Again, this data suggests that SOCS proteins 
can act as positive and negative regulators of signaling pathways and could explain some 
reported anomalies, such as the enhanced insulin signaling observed in transgenic mice 
overexpressing SOCS6 (Li et al., 2004) or the gigantism observed in transgenic mice 
overexpressing SOCS2 (Greenhalgh et al., 2002). 
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3.2.3 Functional roles of SOCS proteins  
The functions of SOCS proteins in vivo have largely been elucidated by the generation of 
mice engineered to lack particular SOCS genes. These studies have greatly enhanced our 
understanding of their roles particularly with regards to the immune response, and have 
also identified key definitive roles of individual SOCS members, such as the non-redundant 
role SOCS1 appears to play in IFN signaling (Alexander et al., 1999). However, this is not 
always the case and knock-out models can encounter problems. Due to placental 
insufficiency, SOCS3-null mice die at mid-gestation (Roberts et al., 2001; Takahashi et al., 
2003) and to overcome this, other ways of investigating SOCS3 deficiency have been 
explored. A genetic cross study conducted by Robb et al. (2005) showed that mice on a 
double LIF/SOCS3-null background were rescued from embryonic lethality due to placental 
failure, and the mice appeared normal at birth (Robb et al., 2005). It is believed that the 
deletion of SOCS3 leads to dysregulated LIF signaling, which alters trophoblast 
differentiation and causes placental defects (Boyle & Robb, 2008). In support of this is the 
finding that the number of trophoblast giant cells are reduced in LIFR-null mice, compared 
with an abnormally high number of trophoblast giant cells in SOCS3-null mice (Takahashi et 
al., 2003). Although embryonic lethality is rescued, a high neonatal mortality rate is 
observed in SOCS3-/-LIF-/- null mice and adult animals develop a fatal inflammatory disease 
very similar to that seen in mice with a conditional deletion of SOCS3 in haematopoietic 
cells (Croker et al., 2003). On the other hand LIF-/- mice have a normal lifespan and do not 
exhibit any major haematopoietic abnormalities, suggesting that SOCS3 plays a vital role in 
the negative regulation of the inflammatory response. 
Another way to overcome SOCS3 embryonic lethality is the generation of conditional knock-
outs using the inducible Cre recombinase (Cre)-loxP system. In this way, the modified target 
gene can be ablated in adulthood, thus avoiding the placental insufficiency observed with 
constitutive global SOCS3 knockouts, and the ablation of the gene can be targeted to any 
tissue at a defined time. This is a powerful tool for the examination of genes that appear to 
be crucial during embryonic development but may also play important roles in particular 
adult tissues. Using these systems, the SOCS3 gene has been specifically deleted in the liver 
and in macrophages. The absence of SOCS3 results in sustained STAT3 and STAT1 
activation following IL-6 treatment, but normal activation of STAT1 in response to IFN and 
normal activation of STAT3 in response to IL-10 (Croker et al., 2003; Lang et al., 2003). 
SOCS3 deficiency was also shown to trigger up-regulation of several IFN-responsive genes 
following IL-6 treatment, which is not normally observed upon IL-6 stimulation of cells with 
functional SOCS3 alleles. This suggested that in the absence of SOCS3, sustained STAT1 
activation provokes a dominant IFN-like gene expression response. Furthermore, a mutation 
in gp130 (Tyr757Phe) in mice, which impedes SOCS3 and/or SHP2 recruitment, was shown 
to result in a phenotype displaying characteristics of RA, a condition already well 
established to be associated with deregulation of IL-6 signaling (Atsumi et al., 2002). 
Collectively, these studies demonstrate that SOCS3 is the main physiological regulator of IL-
6 signaling and that SOCS3 can regulate the “identity” of the cytokine response as well as 
the duration of the signal (Croker et al., 2003; Lang et al., 2003).  
Interestingly, in the absence of SOCS3 in mouse macrophages, IL-6 has been shown to 
induce an “IL-10-like” anti-inflammatory response, as demonstrated by a reduction in LPS-
induced production of TNFǂ and IL-12 (Yasukawa et al., 2003). This is an interesting 
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observation because until this point there was no obvious explanation as to why these two 
cytokines should have such diverse effects. Both cytokines use identical JAK-STAT members 
and yet have very distinct gene expression patterns (Murray, 2007; O’Shea & Murray, 2008). 
IL-10 has been shown to be anti-inflammatory in macrophages and dendritic cells, activating a 
different set of genes from IL-6, but both cytokines also activate a common pool of genes, 
including SOCS3 (Murray, 2007). Yasukawa et al. (2003) proposed that the difference in gene 
expression may be due to the intensity of the STAT3 signal. However, Murray (2007) has 
identified flaws in this concept; for example the strength of the signal does not account for the 
commonality of genes activated by the two cytokines. One obvious difference between the two 
cytokines is the involvement of SOCS3 as an inhibitory regulator of IL-6 but not IL-10 
signaling. Studies have shown that if modified receptors are used, which are either naturally 
insensitive to SOCS3 (e.g. IL-22R) or engineered to be insensitive (e.g. IL-6, leptin receptors) 
but still activate STAT3, an anti-inflammatory response is triggered (El Kasmi et al., 2006). 
Thus, based on SOCS3 involvement, a hypothesis has been proposed describing the activation 
of a generic pool of STAT3 by the IL-10R, which is not subjected to any inhibition by SOCS3. 
The IL-6R, on the other hand may activate a different pool of STAT3 which can be specifically 
inhibited by SOCS3, possibly via post-translational modification by kinases, phosphatases, 
methylases or other regulators. These distinct STAT3 pools may therefore go on to activate 
different sets of genes. However, this is just one idea and ultimately ChIP-Seq experiments will 
be necessary to identify any differences in the genomic locations to which STAT3 can be 
recruited following stimulation with either IL-10 or IL-6. 
With regards to leptin signaling, mice with a neural-specific deletion of SOCS3 have been 
generated using the Cre-loxP system. Similar to the observations for IL-6, SOCS3 deletion 
resulted in prolonged activation of STAT3 in response to leptin. Moreover, SOCS3-deficient 
mice exhibited a greater weight loss compared to their wild-type littermates. These knock-out 
mice were also resistant to high fat diet-induced weight gain and hyperleptinaemia, and 
retained insulin sensitivity. This study showed that SOCS3 is a key regulator of leptin 
signaling and hence plays an important role in diet-induced leptin and insulin resistance (Mori 
et al., 2004). A number of studies support this link between SOCS3 and leptin resistance, 
whereby leptin-mediated induction of SOCS3 has been associated with the attenuation of 
ObRb signaling (Bjorbaek et al., 1998). Chronic stimulation of ObRb has been shown to result 
in the desensitisation of ObRb signaling, whereby the receptor becomes refractory to re-
stimulation. Mutation of the STAT3 binding site on ObRb (Tyr1138Phe), which mediates 
STAT3-induced SOCS3 induction, alleviates this feedback inhibition. Moreover, RNAi-
mediated knock-down of SHP2 had no effect on the attenuation of ObRb signaling, suggesting 
a role for SOCS3 in the feedback inhibition of ObRb signaling and not SHP2 (Dunn et al., 2005). 
Consistent with a role for SOCS3 as a central regulator of  leptin responsiveness, it has been 
shown recently that the ability of  intracellular cAMP sensor Epac1 (exchange protein directly 
activated by cAMP-1) to trigger the induction of SOCS3 (Sands et al., 2006) blocks multiple 
signaling pathways downstream of the leptin receptor ObRb, thus suppressing leptin function 
in hypothalamic pro-opiomelanocortin neurons (Fukuda et al., 2011). 
3.3 Protein Tyrosine Phosphatases (PTPs) 
Protein phosphatases reverse the effects of protein kinases by catalysing the removal of 
phosphoryl groups to initiate, sustain or terminate signals (Andersen et al., 2001). Protein 
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tyrosine phosphatases (PTPs) comprise a large family of these proteins and are 
distinguished by a unique signature motif. Residues in this motif form the phosphate-
binding loop and two residues (a Cys and Arg) are critical for the catalytic activity of PTPs 
(Andersen et al., 2001; Tiganis & Bennett, 2007). PTPs can be grouped into two general 
families; (1) the Tyr-specific PTPs, which can dephosphorylate substrate proteins on Tyr; 
these can be further sub-divided into transmembrane receptor-like PTPs and non-
transmembrane PTPs, and (2) the dual-specificity phosphatases (DUSPs), which can 
dephosphorylate protein substrates on Tyr, Ser and Thr (Tiganis & Bennett, 2007). Our 
understanding of PTPs is greatly lagging behind that of PTKs, partly due to the discovery of 
PTKs a decade before PTPs. However like most kinases, PTPs exhibit a high degree of 
specificity towards their substrates. This is achieved by the PTP catalytic domain, which 
recognises phosphorylated Tyr residues and the flanking amino acids within the substrate, 
and the non-catalytic N- and C- terminal domains, which target the PTP to particular 
intracellular compartments for substrate recognition (Andersen et al., 2001). This is 
exemplified by the DUSPs, which dephosphorylate MAPKs on Tyr and Thr residues. Of the 
10 members that make up this family, some can specifically target one class of MAPK (e.g. 
DUSP6/MKP-3 which dephosphorylates ERK1,2) while others can target more than one 
MAPK class (e.g. DUSP1/MKP-1 which can dephosphorylate ERK, JNK and p38 MAP 
kinases) (Owens & Keyse, 2007). 
Given their importance in cytokine signaling, we will describe three PTPs in detail: PTP1B, 
TC-PTP and SHP2. 
3.3.1 PTP1B 
The prototypical PTP is PTP1B, which was first identified in 1988 (Charbonneau et al., 1988). 
It has been shown to have numerous substrates, but the most extensively studied of these 
include the insulin receptor (IR) and JAK2 (Tiganis & Bennett, 2007). Much of this 
information has come from analysis of PTP1B-null mice, which exhibit enhanced insulin 
sensitivity resulting from increased insulin-stimulated Tyr phosphorylation of the insulin 
receptor in muscle and liver. Furthermore, these mice are resistant to diet-induced obesity 
(Elchebly et al., 1999). Additional studies have since revealed the involvement of leptin 
signaling in the above phenotype and have demonstrated PTP1B inhibition of leptin 
signaling via dephosphorylation of JAK2 (Cheng et al., 2002). 
3.3.2 T cell PTP (TC-PTP) 
T-cell-specific protein tyrosine phosphatase (TC-PTP), which as the name suggests was 
originally cloned from a peripheral T cell cDNA library, is a ubiquitously expressed PTP. 
The primary transcript is processed into two splice variants that encode TC45 and TC48 
isoforms. The resulting differences in primary sequence at the C-terminal domains of TC45 
and TC48 are responsible for their distinct intracellular localization patterns (Lorenzen et al., 
1995). Specifically, TC45 is localized to the nucleus due to a R378KRK sequence, while TC48 
is localized to the endoplasmic reticulum by its unique C-terminal 19 amino acids (Lorenzen 
et al., 1995). The nuclear TC45 isoform has several proposed substrates, including the IR and 
EGFR (Tiganis & Bennett, 2007), JAK1 and JAK3 (Simoncic et al., 2002), and also STAT1 and 
STAT3 (ten Hoeve et al., 2002; Yamamoto et al., 2002). Of interest, Yamamoto et al. (2002) 
have demonstrated TC45-mediated suppression of STAT3 activation in response to IL-6 in 
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293T cells, implicating the nuclear isoform of TC-PTP as an important negative regulator of 
IL-6 signaling. This is supported by studies of TC-PTP-deficient mice, which display a more 
complex phenotype as compared to mice deficient in the closely related PTP1B. Specifically, 
TC-PTP-null mice are viable but exhibit profound defects, resulting in splenomegaly, 
lymphadenopathy and thymic atrophy. As a result, the mice typically die at 3-5 weeks. 
Homozygous mice display defects in bone marrow, B cell lymphopoiesis, erythropoiesis, 
and impaired T and B cell functions. Taken together, the abnormalities displayed in TC-
PTP-deficient mice strongly suggest a crucial role in haematopoiesis and immunity (You-
Ten et al., 1997). However, targeted deletion of TC-PTP in defined cell types will 
undoubtedly reveal previously unknown aspects of its function. For example, a recent study 
has shown mice lacking TC-PTP in neurons are hypersensitive to leptin and are resistant to 
diet-induced weight gain compared with WT animals (Loh et al., 2011). Animals in which 
both PTP-1B and TC-PTP were deleted showed additive effects compared with the single 
knockouts, suggesting that both PTPs regulate ObRb signaling. However, it was found that 
TC-PTP levels are elevated in hypothalamus extracts from obese mice, raising the possibility 
that this may contribute relatively more to the leptin resistance observed in obesity (Loh et 
al, 2011; Myers et al., 2008). 
3.3.3 SH2 domain-containing PTP 2 (SHP2) 
The SH2-domain containing PTPs (SHPs) are a subfamily of non-transmembrane PTPs 
comprising two vertebrate members, SHP1 and SHP2. While SHP1 expression is restricted 
to cells of the haematopoietic system, SHP2 is ubiquitously expressed. Both proteins contain 
two N-terminal SH2 domains (N-SH2 and C-SH2) and a C-terminal catalytic PTP domain. 
As such, both proteins have the unique ability to function as PTPs, dephosphorylating 
signaling components and thus inhibiting signal transduction, whilst also serving as adapter 
molecules via their SH2 domains to recruit further adapter molecules and activate 
downstream signaling (Heinrich et al., 2003; Neel et al., 2003). Both SHP1 and SHP2 appear 
to have non-redundant roles since homozygous deletion of either gene in mice results in 
death at 2-3 weeks due to severe inflammation. The SHP1-null phenotype is termed 
“motheaten” because of the patchy hair loss caused by sterile dermal abscesses (Neel et al., 
2003) while SHP2 deletion produces embryonic lethality due to defective gastrulation or 
mesodermal differentiation (Neel et al., 2003). Thus, one SHP does not appear to 
compensate for the other in these phenotypes. The functional differences between SHP1 and 
SHP2 appear to be due to the differences in SH2 domain-mediated protein interactions, as 
well as differences in the PTP domains of both proteins (Salmond & Alexander, 2006).  
The finding that ERK1,2 activation by IL-6 is inhibited in either knock-in mice expressing a 
Tyr759Phe-mutated gp130  (gp130F759/F759) or cells transfected with a mutated Tyr759Phe 
gp130 construct, establishes a positive regulatory role of SHP2 on the ERK1,2 pathway (Kim 
& Baumann, 1999; Ohtani et al., 2000). Indeed, studies on growth factor receptor signaling, 
including EGF, insulin and platelet-derived growth factor (PDGF) signaling have each 
demonstrated a positive regulatory role of SHP2 on ERK1,2 signaling and gene expression 
(e.g. Yamauchi et al., 1995). In contrast to these positive effects, gp130F759/F759 mice and cells 
transfected with a Tyr759Phe-mutated gp130 demonstrate impaired SHP2 activation, 
prolonged STAT3 and STAT1 activation and enhanced acute-phase protein gene induction, 
suggesting a negative role of SHP2 on the STAT pathway (Ohtani et al., 2000; Schaper et al., 
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1998). In support of this negative regulatory role, the gp130F759/F759 mouse displays 
splenomegaly, lymphadenopathy and an enhanced acute phase reaction (Ohtani et al., 
2000). However, these results are complicated by the findings that SOCS3 binds to the same 
PTyr site on gp130 as SHP2 (De Souza et al., 2002) and could therefore potentially contribute 
towards these negative effects. To address this issue, studies have employed catalytically 
inactive dominant-negative SHP2 mutants in gp130 signaling. Expression of these mutants 
result in increased gp130, JAK and STAT3 phosphorylation as well as elevated gene 
induction (Lehmann et al., 2003; Symes et al., 1997), thus confirming the involvement of 
SHP2 in the negative regulation of the STAT pathway activated by gp130. 
These negative effects of SHP2 on gp130 signaling may be receptor-specific as they do not 
appear to be observed for signaling from the leptin receptor ObRb, since mutation of SHP2 
binding site Tyr985 of ObRb has no effect on STAT activation (Li & Friedman, 1999). Also, 
using dominant negative SHP2 strategies in COS-1 cells, SHP2 was shown not to have an 
effect on STAT3 phosphorylation or STAT3-mediated gene transcription from the SOCS3 
promoter (Bjorbaek et al., 2001). However, these studies demonstrated no effect of SHP2 on 
STAT activation and STAT-dependent promoter activity following 15 minutes and 6 hours 
of leptin treatment respectively. Further research by this group has demonstrated that 
following 24 hours of leptin treatment, STAT-mediated transcription was enhanced in cells 
expressing mutated Tyr985Phe ObRb (Bjorbaek et al., 2001) and suggested that the induction 
of SOCS3 by leptin over prolonged leptin treatment could account for the enhanced STAT3 
response, implicating SOCS3 involvement and not SHP2. In addition, over these extended 
periods of leptin treatment, SHP2 could possibly act as an indirect positive regulator of the 
STAT pathway, preventing SOCS3 binding to the ObRb at Tyr985 (Bjorbaek et al., 2001). 
Thus, in general, a positive role of SHP2 in cytokine-induced ERK1,2 activation and a 
negative or positive role of SHP2 in cytokine-induced STAT activation have been proposed. 
How SHP2 mediates this positive effect on ERK activation and the contribution of SHP2 to 
the negative regulation of STAT signaling in relation to SOCS3 are still areas under 
investigation. To address the first point, SHP2 appears to exert a positive effect on ERK 
signaling by acting as an adapter protein, wherein SHP2 becomes recruited to PTyr residues 
on activated cytokine receptors and following activation, associates with the adapter protein 
Grb2, which is bound to the Ras GDP-GTP exchange factor Sos. The membrane-localised 
Grb2/Sos complex can then go on to activate the Ras-Raf-MAK-ERK pathway (Li et al., 
1994). With regards to gp130 signaling, it has been proposed that the SHP2-Grb2/Sos mode 
of ERK activation is adopted (Heinrich et al., 2003). However, in addition to this model, 
Grb2-associated binder-1 (Gab1) has also been shown to become tyrosine phosphorylated to 
associate with SHP2 and phosphatidylinositol 3-kinase (PI3K) to activate ERK in response to 
IL-6 (Takahashi-Tezuka et al., 1998). Alternatively, SHP2 may act as a PTP, thus 
dephosphorylating and inactivating specific substrates that normally suppress ERK1,2 
activation. For example, SHP2 has been shown to dephosphorylate tyrosine residues on 
EGFR required for RasGAP recruitment to the receptor, thereby inhibiting phosphorylation-
dependent translocation of RasGAP to the plasma membrane and thereby maintain Ras-
GTP levels to sustain ERK1,2 activation (Agazie & Hayman, 2003).  
Finally a model has been proposed whereby the binding of SHP2 to PTyr residues has been 
shown to activate its PTP activity via either of two mechanisms (Barford & Neel, 1998); (1) 
the SH2 domains can bind to PTyr motifs on activated receptors such as pTyr759 on gp130, 
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which leads to unfolding of the protein and subsequent activation of phosphatase activity, 
or (2) the SH2 domains can bind to PTyr542 and 580 on the C-terminal tail of SHP2 itself and 
cause conformational changes leading to activation. If PTyr binding does not occur, SHP2 
remains in an inactive state whereby the N terminal SH2 (N-SH2) domain sterically hinders 
access of phosphorylated substrates to the PTP domain, as demonstrated by its crystal 
structure (Hof et al., 1998). Therefore, the N-SH2 domain of SHP2 can either bind and inhibit 
the phosphatase, or bind to PTyr residues on substrates to activate the enzyme. 
Interestingly, in the human autosomal dominant disorder Noonan Syndrome, 
approximately 50% of all cases are caused by mutations in the SHP2 gene PTPN11, and 
specifically in portions of the amino N-SH2 domain. These mutations lock SHP2 in its active 
conformation and subsequently cause excessive SHP2 activity (Tartaglia et al., 2001). 
Noonan Syndrome is characterised by short stature, cardiac defects, facial dysmorphia and 
an increased risk of developing leukaemia (Salmond & Alexander, 2006). Interestingly this 
syndrome displays aberrant hyperactivation of the ERK1,2 pathway (Bentires-Alj et al., 
2006). Thus, Noonan Syndrome demonstrates an involvement of SHP2 in regulating ERK 
activation in human disease although further research is required to better understand the 
exact mechanisms involved. 
Likewise, the mechanisms by which SHP2 negatively or positively regulates STAT 
activation are not well understood and the relative contribution of both SHP2 and SOCS on 
gp130 or ObRb signaling is still unclear. There are reports showing that SHP2 can act 
directly as a STAT phosphatase (Chen et al., 2003) and STAT3/SHP2 complexes have been 
detected in cells (Gunaje & Bhat, 2001). A large body of evidence supporting a negative role 
of SHP2 in gp130-mediated STAT activation exists, whereas conversely, SHP2 has been 
shown to have no effects on ObRb-mediated STAT3 phosphorylation (Bjorbaek et al., 2001). 
Therefore the possibility exists that SHP2 acts as an indirect positive regulator of STAT3 by 
impeding SOCS3 recruitment at PTyr985 (Bjorbaek et al., 2001). 
4. Cross-regulation of signaling pathways via SOCS proteins 
Cells are typically exposed to a changing milieu of cytokines and other extracellular 
regulators. Therefore to produce an appropriate response, effective crosstalk between 
distinct signaling pathways is essential. In terms of cytokine receptor signaling, the levels at 
which such crosstalk can occur are now beginning to be revealed, and here we will discuss 
two recently characterized examples of this type of regulation. 
4.1 Regulation of SOCS3 expression by cAMP/Epac1 
Many studies have shown that prototypical second messenger cAMP exerts profound anti-
inflammatory and immunosuppressive effects on many target cell types, including vascular 
endothelial cells, neutrophils,  monocytes, CD4 T cells and regulatory T cells (Mosenden & 
Tasken, 2011). Many of these effects are mediated via defined gene transcription 
programmes, which include the up-regulation of protective molecules, such as the 
immunosuppressive cytokine IL-10, while down-regulating pro-inflammatory molecules 
such as TNF and IL-1 (e.g. Wall et al., 2009). A large body of research has identified 
members of the cAMP-response element binding (CREB) protein family as the principal 
mediators of changes in gene expression in response to cAMP following their 
phosphorylation by PKA. However, observations of cAMP-mediated induction of specific 
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genes occurring via PKA-independent mechanisms have demonstrated that other mechanisms 
must also exist. For example, we have demonstrated that cAMP elevation is capable of 
inducing the SOCS3 gene via a PKA-independent mechanism that requires Epac1 (Sands et al., 
2006; Woolson et al., 2009). Epac1 and Epac2 were originally identified as guanine nucleotide 
exchange factors (GEFs) for the Rap 1 and Rap2 small GTPases. Each has several important 
structural features, including a cyclic nucleotide binding domain (Epac2 has two such 
domains), a DEP (Dishevelled, Egl, Pleckstrin) domain, a REM (Ras exchanger motif) domain 
and a Cdc25 homology domain that exhibits GEF activity (Borland et al., 2009b). Identification 
of SOCS3 as an Epac-regulated target gene revealed a new mechanism by which cAMP could 
inhibit signaling from specific SOCS3-targeted cytokine receptors, such as the leptin receptor 
ObRb and gp130 (Sands et al., 2006; Fukuda et al., 2011). The mechanism of SOCS3 induction 
is mimicked by expression of a constitutively active Val12 mutant of Rap1a and is blocked by 
either siRNA-mediated depletion of Rap1 or overexpression of RapGAPII, suggesting that the 
ability of Epac1 to stimulate the accumulation of GTP-bound active Rap1 is essential (Yarwood 
et al., 2008). Rap1 then activates phospholiase C  to generate intracellular sn 1,2-diacylglycerol 
(DAG) and mobilize intracellular calcium, resulting in the activation of specific protein kinase 
C isoforms (Borland et al., 2009a), although exactly how PKC regulates SOCS3 transcription is 
unclear. 
We have also identified the transcription factor(s) targeted by Epac1, demonstrating that Epac1 
activation increases the binding of the CCAAT/enhancer binding protein  (C/EBP to a 
region within the human SOCS-3 promoter enriched in C/EBP-responsive elements in 
vascular endothelial cells in situ. In addition, overexpression of specific C/EBP isoforms in 
endothelial cells can potentiate Epac-mediated induction of SOCS-3, while selective 
knockdown of either C/EBP or C/EBP abolishes induction. Similar experiments performed 
on C/EBP knockout murine embryonic fibroblasts have confirmed these findings. 
Interestingly, SOCS3 induction in response to cAMP requires activation of the ERK1,2 
pathway, which triggers phosphorylation of C/EBP on Thr225. The importance of this event 
is demonstrated by the ability of Thr225Ala-mutated C/EBP to function as a dominant-
negative inhibitor of SOCS3 induction (Borland et al., 2009a). However, siRNA-mediated 
depletion of Epac1 fails to diminish cAMP-stimulated ERK1,2 phosphorylation, which occurs 
via a PKA-independent mechanism, suggesting that an additional PKA-independent pathway 
is involved in C/EBP-mediated SOCS3 induction (Woolson et al., 2009). 
While a role for specific transcription factors has yet to be addressed, characterisation of the 
induction of the pro-glucagon and AQP2 genes in response to cAMP has revealed some 
similarities to the induction of SOCS3. In each case, induction by cAMP-elevating agents is 
resistant to inhibition of PKA and can be mimicked by selective activation of Epac by the 
Epac-selective activator 8CPT-2’-O-Me-cAMP. There also appears to be a requirement for 
activation of the ERK1,2 pathway by cAMP (Lotfi et al., 2006; Umenishi  et al., 2006). These 
similarities would suggest that the PKA-independent mechanisms by which the pro-
glucagon, AQP2 and SOCS3 genes are induced in response to cAMP may be related and 
presumably apply to other yet to be identified  Epac-inducible genes. 
4.2 Regulation of multiple steps within the NF-B pathway by SOCS proteins 
Given that SOCS family members each contain an SH2 domain, it is not surprising that their 
influence on cellular processes have been found to extend beyond classical JAK-STAT 
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signaling processes. These include the inhibition of insulin signaling due to SOCS3-
mediated ubiquitylation and degradation of IRS1 and/or IRS2 (Kawazoe et al., 2001; Rui et 
al., 2002), and the regulation of FAK1 (Liu et al., 2003; Stevenson et al., 2010). Importantly, 
many studies have also revealed that SOCS proteins are able to regulate the NF-B pathway 
at several levels, providing a key mechanism by which JAK-STAT-mobilising cytokines can 
control pro-inflammatory responses. 
Members of the TLR family of receptors and the receptor for IL-1 trigger an inflammatory 
response via a conserved mechanism. The cytosolic region of these receptors contains a 
Toll/IL-1 receptor (TIR) domain that interacts with a panel of adaptor molecules to activate 
defined intracellular signaling cascades, including p38 and c-Jun N-terminal kinase MAP 
kinase pathways and the NF-B pathway (O’Neill, 2009). While several TIR domain-
interacting proteins have been identified, the best characterized are MyD88 (myeloid 
differentiation  primary response gene 88), Mal (MyD88 adaptor-like), TRIF (TIR domain-
containing domain that induced IFN) and TRAM (TRIF-related adaptor molecule). All 
TLRs activate the NF-B pathway but different receptors utilize specific subsets of adaptors 
to achieve this; for example, both TRAM and TRIF have been shown to be required for 
activation of IRF3/7 and NF-B by TLR4, while the absence of Mal abolishes TLR2- and 
TLR4-stimulated pro-inflammatory cytokine production (O’Neill, 2009; Brikos & O’Neill, 
2008). The requirement for Mal is thought to be due to an interaction with TRAF6 that 
promotes phosphorylation of the RelA subunit of NF-B on Ser536, which is required for 
binding of transcriptional co-activators, rather than any effect on transcription factor 
translocation to the nucleus from the cytosol (Verstak et al., 2009). The ability of SOCS1 to 
regulate TLR-mediated responses has been reported by multiple investigators, but no one 
unifying mechanism has emerged. One study has demonstrated that activation of either 
TLR2 or TLR4 with selective agonists can trigger the proteasomal degradation of Mal but 
not MyD88 (Mansell et al., 2006). Further characterization of this phenomenon revealed that 
this process required the Tyr phosphorylation of Mal by Bruton’s tyrosine kinase (BTK), 
which is also activated by TLRs. Upon SOCS1 induction in response to TLR activation, the 
SOCS1 SH2 domain is thought to bind phosphorylated Mal. Once bound, SOCS1 functions 
as an E3 ubiquitin ligase to catalyse the Lys48 polyubiquitylation of Mal, thereby targeting it 
for degradation by the proteasome, blocking RelA phosphorylation and turning off NF-B-
mediated gene transcription (Mansell et al., 2006) (Fig. 4). However it should be noted that 
others have found that SOCS3 plays an important role in the suppression of IL-1 signaling 
by binding and inhibiting TAK1, a kinase which is required for IL-1 receptor-mediated 
initiation of MAP kinase and NF-B pathways (Frobøse et al., 2006). The significance of this 
interaction for SOCS-mediated suppression of TLR signaling has yet to be investigated. 
Several recent studies have also shown that SOCS1-mediated negative regulation of NF-B 
is not restricted to activation by TIR domain-containing receptors due to its incorporation 
into a multimeric complex by COMMD1 (copper metabolism gene MURR1 domain-
containing protein 1) (Maine & Burstein, 2007). The defining ~70 residue domain conserved 
within all 10 members of the COMMD family is located at their C-termini, and mutation of 
conserved residues within this domain has been shown to ablate inhibition of NF-B. 
Interestingly, COMMD1 appears to associate with the RelA component of NF-B complexes 
on target gene promoters, i.e. after translocation of NF-B from the cytoplasm to the nucleus 
(Maine et al., 2007; Geng et al., 2009). Current research suggests that RelA-bound COMMD1 
then recruits a SOCS1-elongin B/C-Cul2-Rbx1 E3 ubiquitin ligase complex which promotes 
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the polyubiquitylation and proteasomal degradation of RelA, thus turning off NF-B-
mediated target gene transcription (Fig. 4). Accordingly, COMMD1 deficiency results in a 
sustained nuclear accumulation of RelA without affecting nuclear entry of NF B (Maine et 
al., 2007; Geng et al., 2009). 
 
Fig. 4. Control of the NF-B pathway at multiple levels by a elongin-cullin-SOCS1 (ECSSOCS1) 
ubiquitin E3 ligase complex. 
5. Implications for therapeutic strategies to treat chronic inflammatory 
diseases and cancers   
Over the last decade, the importance of chronic inflammation to the pathophysiology of 
non-infectious diseases, including cancers, cardiovascular disease and diabetes mellitus, has 
been established (O'Shea & Murray, 2008). In parallel with these developments, genome 
wide association studies have identified polymorphisms in cytokine receptors and their 
associated signaling molecules associated with autoimmune diseases such as type 1 diabetes 
and inflammatory bowel syndrome (e.g. Rossin et al., 2011), while new therapies have been 
approved deriving from our understanding of how pro-inflammatory signaling drives 
pathology (e.g. anti-TNF and IL-6 antibodies for RA and other indications) and several more 
are in development (e.g. JAK inhibitors) (Taylor & Feldmann, 2009;  Ding et al., 2009; 
Quintás-Cardama et al., 2011). 
5.1 Polycythaemia Vera (PV) and other myoproliferative neoplasms 
Myoproliferative neoplasms arise from either haematopoietic stem or progenitor cells, and 
are characterized by the proliferation of terminally differentiated myeloid cells (Quintás-
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Cardama et al., 2011). Along with essential thrombocythaemia (ET) and primary 
myelofibrosis (PMF), polycythaemia vera (PV) represents one of the most studied classes 
of myoproliferative neoplasms, with patients displaying hyperactivation and proliferation 
of haematopoietic stem cells in bone marrow, resulting in increased production of 
platelets, white and red blood cells (Quintás-Cardama et al., 2011). The importance of 
JAK2 in haematopoiesis had already been established from studies demonstrating that 
homozygous JAK2 deletion produces embryonic lethality due to insufficient 
erythropoeisis. This arises due to the pivotal role of JAK2 activation downstream of 
receptors for cytokines that drive this process, including Epo, thrombopoietin (Tpo), G-
CSF, and GM-CSF (Rane & Reddy, 2002). It was subsequently found that approximately 
95% of patients presenting with PV have a G-to-T substitution at position 1849 of the JAK2 
gene that results in a Val617Phe dominant gain-of-function mutation within the JH2 
domain (JAK2V617F) (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et 
al., 2005) (Fig. 1). As mentioned previously, a recent study demonstrating that the JH2 
domain functions as a dual specificity kinase module has shown that the ability of the JH2 
domain to suppress JAK2 Tyr kinase activity is disrupted by the Val617Phe mutation due 
to a reduced JH2-mediated regulatory phosphorylation of Ser523 and Tyr570 (Ungureanu 
et al., 2011). Additional studies examining those PV patients who are JAK2V617F-negative 
have found that the phenotype is associated with additional mutations within exon 12 of 
the JAK2 gene. Thus, essentially all cases of PV appear to be driven by somatic activating 
mutations within the JAK2 gene. 
Not surprisingly, expression of Val617PheJAK2 activates signaling pathways that drive 
proliferation and resistance to apoptosis in a cytokine-independent manner. STAT3 and 
STAT5, as well as the ERK1,2 and PI3K pathways, are the main effectors of JAK2 activation 
responsible for the PV phenotype. However it has also recently been proposed that 
Val617PheJAK2 is resistant to the suppressive effects of SOCS induction. In fact, SOCS3 
appears to specifically enhance downstream activation of STAT5 in Epo receptor- and 
Val617PheJAK2-expressing cells (Hookham  et al., 2007). The mutated JAK2 was also found 
to enhance the Tyr phosphorylation of SOCS3, and this has been proposed as the 
mechanism by which SOCS3 is rendered incapable of blocking signaling from the Epo 
receptor and activated Val617PheJAK2. Conversely, others have found that both SOCS1 and 
SOCS3 are still capable of binding and regulating Val617PheJAK2 expression levels by 
targeting it for degradation: indeed the mutated constitutively active JAK2 was found to 
have a reduced stability compared with WT JAK2 (Haan et al., 2009). Furthermore, the 
authors found that Val617PheJAK2 expression levels have to exceed a minimum threshold 
before cytokine-independent constitutive activation of downstream signaling is observed, 
and they propose that such a scenario may explain progression to homozygocity in 
myoproliferative neoplasms such as PV (Haan et al., 2009). Perhaps related to this 
observation, the expression ratio of mutated to wild-type JAK2 seems to modulate the 
phenotypic manifestations of myoproliferative neoplasms, with high ratios favouring the 
development of a PV-like phenotype and low ratios inducing an ET-like phenotype 
(Kralovics et al., 2005). In this context, the hypermethylation-mediated  silencing of SOCS 
gene induction seen in idiopathic myelofibrosis (Fourouclas et al., 2008) would be predicted 
to play an important role in determining pathological severity arising from somatic 
activating JAK2 mutations. 
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Given their role in disease and their ability to recapitulate disease phenotypes in mouse 
models, mutated JAK2 proteins represent attractive targets for drugs to treat myoplastic 
neoplasms. Incyte’s ruxolitinib, an orally available non-selective JAK1/JAK2 inhibitor and 
one of the first of these agents to be developed, has been shown to improve symptoms such 
as itching and reduce spleen size in PMF patients but without producing observable 
remission (Verstovsek et al. 2010; Tefferi et al., 2011). Remarkably, these effects occur 
regardless of whether the JAK2V617F allele is present. Therefore, determining exactly how this 
class of drugs can exert its effects is necessary if clinical efficacy is to be improved. It has 
been suggested that the lack of selectivity of ruxolitinib may be responsible for its limited 
efficacy in PMF, but comparable studies with more selective inhibitors such as LY3009104 
(Lilly, currently in phase II trials for RA), which is approximately 40-fold more selective for 
JAK2 versus JAK1, will be required to address this issue. Tofacitinib (Pfizer, currently in 
phase III trials for multiple immune/inflammatory disorders including psoriasis and RA) 
was initially developed as part of a strategy to develop JAK3-selective inhibitors but upon 
detailed characterization was also shown to have significant activity against JAK1 and JAK2. 
Encouragingly, JAK inhibitors such as tofacitinib have shown efficacy in several models of 
JAK2V617F–mediated proliferation (Manshouri et al., 2008) and therefore may prove useful if 
ultimately approved for their primary indications. 
However, as with almost all kinase inhibitors currently used for treatment of 
hyperproliferative disorders such as chronic myelogenous leukaemia (Diamond & Melo, 
2011), there is the strong possibility of drug resistance developing following chronic drug 
administration. Thus, new drug-resistant activating JAK2 point mutations will likely emerge 
and alternative signaling pathways able to drive proliferation and resistance to apoptosis 
may be up-regulated to bypass drug-mediated inhibition of JAK2 (Deshpande et al., 2011). 
As a result, there will undoubtedly be a need to develop additional therapeutics for 
myeloproliferative disorders to account for these possibilities once first generation JAK 
inhibitor drugs have been approved. 
5.2 RA and other autoimmune disorders 
RA is a chronic, systemic autoimmune/inflammatory disease that predominantly results in 
the deterioration of synovial joints, although other tissues may be affected. The disease 
process often typically leads to the destruction of articular cartilage and ankylosis of the 
joints, resulting in discomfort and pain for affected individuals. Key cytokines involved in 
driving pathogenesis include TNF, IL-1 and IL-6, which exert their effects on immune cells 
and synovial fibroblasts (Feldman et al., 1996). Up until approximately ten years ago, the 
treatment options for RA were limited to disease-modifying anti-rheumatic drugs 
(DMARDs) such as methotrexate, sulphasalazine and leflunomide. While DMARDs are 
effective for the majority of patients, a significant proportion display adverse reactions to 
chronic administration, including renal and hepatotoxic effects. This has led to the 
development of several biological drugs designed to block cytokine receptor activation by 
binding and sequestering free cytokine to prevent engagement with the cognate receptor, 
and each is typically administered either as part of a combination therapeutic regimen with 
one or more DMARDs or as monotherapy in patients not able to tolerate DMARD therapy 
or for whom it has proven ineffective. They include TNF blockers (e.g. etanercept, 
infliximab and adalimumab, the first fully human antibody drug to be FDA approved) and 
IL-1 blockers (e.g. anakinra) (Taylor & Feldmann, 2009; Gabay et al., 2010). 
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One of the more recently approved biological therapies is the humanized antibody 
tocilizumab, which blocks IL-6 signaling by binding to the IL-6R to prevent receptor 
activation (Ding et al., 2009). The development of IL-6 blockers came from a wealth of 
research implicating this pleiotropic cytokine in the progression of RA and other 
autoimmune conditions at several levels. Seminal studies demonstrated that patients with 
RA, but not osteoarthritis, had elevated levels of synovial IL-6, thereby linking the cytokine 
to an autoimmune syndrome (Hirano et al., 1988). Studies of knock-in mice expressing a 
Tyr759Phe-mutated gp130 resistant to SOCS3-mediated inhibition and incapable of 
activating ERK1,2 demonstrated that these animals spontaneously developed an RA-like 
autoimmune disease, implicating IL-6 activation of STAT3 as a key mediator of the 
pathology (Atsumi et al., 2002). Additionally, IL-6 via activation of STAT3 can induce the 
expansion of Th17 cells, which are intimately involved in the development of several 
autoimmune diseases including RA. In addition, IL-17A can trigger the induction of IL-6 in 
synovial fibroblasts, thereby creating a positive feedback loop that sustains the chronic pro-
inflammatory state (Ogura et al., 2008). IL-6 has also been found to suppress generation of 
Treg cells, which restrain effector T cell responses (Hirano, 2010). The balance between these 
two subsets is critical for maintaining homeostasis, and so the ability of IL-6 to drive the 
balance in favour of Th17 cell dominance is likely to be a be a major cause of pathology in 
RA and other disorders. Interestingly, it was also found that Tyr759Phe-mutated gp130 
must be present in non-haematopoietic cells, and that in response to IL-6 stimulation non-
haematopoietic cells expressing Tyr759Phe-mutated gp130 show enhanced production of IL-
7, leading to the activation and proliferation of CD4+ T cells (Sawa et al., 2006). These 
observations demonstrate that IL-6-regulated immune and non-immune cell interactions are 
critical in the development of RA, and suggest that such interactions may play a similar 
etiological role in other autoimmune diseases in which IL-6 plays an integral role such as 
psoriasis, uveitis and inflammatory bowel disease. 
5.3 STAT3 activation and tumour development 
Mutational activation of proto-oncogenes, coupled with the mutational inactivation of  
tumor suppressors, are critical events in pathogenesis of cancers (Hanahan & Weinberg, 
2011). However several genes that play pivotal roles in the development of malignancies are 
not activated by mutation. These include the STATs (particularly STAT3) and NF-B 
transcription factors, which are activated by extracellular stimuli generated within the 
tumor microenvironment (Grivennikov & Karin, 2010). As described earlier in this chapter, 
STATs are typically activated transiently due to the existence of multiple negative feedback 
mechanisms that act at several levels to terminate signaling, and the same is true for 
activation of both the canonicical and non-canonical NF-B pathways (Liu & Chen, 2011). 
Thus, activated nuclear STAT3 is found in many cancers, including breast, colon and 
prostate among others (Grivennikov et al., 2009; Marotta et al. 2011; Hedvat et al., 2009). 
Hyperactivation of STAT3 in infiltrating immune cells and stromal cells is due to the 
presence of multiple STAT3-activating stimuli, including IL-6 and other cytokine capable of 
utilizing gp130, IL-10 family members and also receptor tyrosine kinases for VEGF and EGF. 
Importantly, several of the STAT3-inducible gene products generated by these stimuli, 
including IL-6 itself, IL-10, IL-23, sphingosine-1-phosphate receptor S1P1, and angiogenic 
growth factor VEGF, perpetuate a positive feedback loop that promotes sustained 
pathogenic STAT3 activation within the tumour (Yu et al., 2009; Lee et al., 2010). In 
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conditions such as hepatocellular carcinoma, malignant melanoma, prostate cancer and 
others, this STAT3 activation loop can be amplified further due to methylation of the CpG 
island within the SOCS3 gene promoter, thereby blocking its induction (Niwa  et al., 2005; 
Fourouclas et al., 2008; Pierconti et al., 2011). Indeed, SOCS3 hypermethylation has been 
shown to be associated with prostate cancer tumours with a high Gleason score, suggesting 
a causative role in pathogenesis (Pierconti et al., 2011). 
Importantly, while STAT3 and NF-B trigger distinct gene expression programmes in 
various cell types, many gene products are induced by both, including IL-6, VEGF, 
chemokines CCL2 and CXCL2, anti-apoptotic proteins Bcl-XL and Bcl-2, and SOCS3 (Yu et 
al., 2009). The different mechanisms by which STAT3 and NF-B (predominantly the 
RelA/p50 heterodimer) interact to enhance target gene transcription have been shown to be 
context-dependent but typically result in enhanced target gene induction. For example, 
Tyr705-phosphorylated STAT3 has been shown to bind promoter-bound RelA to facilitate 
the recruitment of the transcriptional co-activator p300, thereby triggering RelA acetylation. 
As a result, interaction with IB is inhibited, resulting in reduced export of 
RelA/p50/IB complexes and thereby prolonging its nuclear localization and potentially 
its transcriptional capacity even if upstream IKK-mediated signaling is only weakly 
activated (Lee et al., 2009). Other groups have identified a different mechanism whereby 
non-phosphorylated STAT3 can displace IB from inactive RelA/p50 complexes in the 
cytoplasm, thereby facilitating nuclear entry in the absence of IKK activation and the 
subsequent induction of a subset of B-responsive genes such as the chemokine RANTES 
(Yang et al., 2007). Interestingly, evidence suggests that NF-B/STAT3 complexes are 
capable of binding to target sequences distinct from those utilized by either transcription 
factor in isolation (Yang et al., 2007; Yang & Stark, 2008). While this phenomenon has only 
been studied in detail for the serum amyloid A gene mobilized as part of the acute phase 
response, it raises the possibility that NF-B/STAT3 complexes may be able to initiate a 
unique transcriptional programme, although any role in tumour progression is still unclear. 
Despite strong evidence that targeting STAT3 might be a useful therapeutic strategy to 
suppress tumour formation, one major limitation stems from its importance in stromal as 
well as haematopoietic cell function. As a result, while pharmacological inhibition of STAT3 
in the former may exert anti-tumourigenic effects, inhibition in the latter may actually 
enhance tumourigenesis, with the net result being limited efficacy. For example, 
homozygous deletion of the murine STAT3 gene in enterocytes has been shown to block the 
development of colitis-associated colon cancer (Grivennikov et al., 2009), whereas its 
deletion in macrophages and neutrophils results in the development of enterocolitis due to 
the inability of IL-10 to suppress myeloid cell function via STAT3 (Takeda et al., 1999). 
Moreover STAT3 has important pro-survival functions in healthy tissues and is central to 
immune cell homeostasis, making it difficult to predict the consequences of chronic global 
inhibition of function. Thus, alternative strategies might include specifically targeting 
tumourigenic cytokines that utilize STAT3, such as IL-6 or IL-23, which would spare the 
protective anti-inflammatory/immunosuppressive functions of STAT3-mobilising cytokines 
such as IL-10. Related to this point, it is been demonstrated in a mouse model of colitis-
associated cancer that TGF-ǃ-dependent suppression of T cell stimulation could enhance IL-
6 expression. A concomitant reduction in membrane-bound IL-6R on epithelial cells coupled 
with an increase in ADAM17 in stromal tissue resulted in the generation of sIL-6R and 
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subsequent trans-signaling (Becker et al., 2004). Tumour growth could be suppressed by the 
administration of sgp130Fc, which specifically blocks trans-signaling by sIL-6R/IL-6 but 
not classical IL-6 signaling through membrane-bound IL-6R. Given that a similar loss of IL-
6R and upregulation of ADAM17 has been described in human colon cancer (Becker et al., 
2007), selective inhibition of IL-6 trans-signaling using sgp130Fc or related therapeutics 
might prove a useful approach to arrest the development of colon cancer and other tumours 
in which a pathophysiological role for IL-6 trans-signaling could be identified. 
6. Conclusions 
Progress in our understanding of the molecular basis of cytokine signaling and the 
subsequent identification of the importance of JAK mutations and hyperactivation of STAT3 
in disease states has improved our understanding of the pathogenesis of RA, PV and several 
cancers. A direct result of this progress has been the development and introduction of JAK 
inhibitors and anti-IL-6 therapies for several inflammatory and autoimmune conditions. 
However our understanding of JAK-STAT signaling, particularly its integration with the 
NF-B and cyclic AMP signaling pathways to regulate immune and inflammatory 
responses, remain incomplete. Moreover, new insights continue to emerge into roles both 
for nuclear-localised JAKs in chromatin remodeling and cell cycle regulation (Zouein et al., 
2011) and links with Rho kinase that control actomyosin contractility, cell migration and 
even STAT3 activation (Sanz-Moreno et al., 2011). Consequently it is likely that the first 
wave of therapies targeting cytokine-activated JAK-STAT pathways is the beginning of 
several new approaches with which to treat the wide range of diseases in which they play a 
critical role. 
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